Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Acne (US)

Articles with lock require a subscription to GLG News | Request a free trial
February 13, 2008
Fears of safety and fears of a black box warning.
Analysis of: FDA Issues Warning About Botox Deaths | www.pharmalot.com
Author: GLG Expert Contributor
Is Botox as safe as we have imagined it to be? The implications of an impending possible black box warning on the cosmetic and medical use of Botox in dermatology.
Sunil DhawanFebruary 12, 2008
FDA Botox warning unlikely to limit cosmetic use
Analysis of: FDA Issues Warning About Botox Deaths | www.pharmalot.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The recent FDA warning on Botox is unlikely to limit the cosmetic use of the product because the dose is relatively low. The warning only applies to significantly  higher doses in patients with neuromuscular conditions like cerebral palsy. Serious adverse events like allergic reactions are very...
Sunil DhawanFebruary 8, 2008
Botox competitors to make market interesting
Analysis of: Efficacy of Botulinum Toxin Does Not Sag Over Time | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Botox is  highly effective cosmetic product, albeit not long lasting. Patient satisfaction is high, and the cost is still not prohibitive. However the predictable and not always justified increases in price have forced many physicians to eagerly await the newer agents. The include products from...
Sunil DhawanFebruary 8, 2008
Enbrel effective in pediatric psoriasis
Analysis of: New Study Reports Enbrel (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents | www.wyeth.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This study will expand the use of Enbrel in newer populations. this is important in that Humira just received approval for adults, and the market has become more competitive. This is good news for children with severe resistant psoriasis.
January 23, 2008
Blue Cross Plan is capitation in a worse plan
Analysis of: New therapy for old woes, Blue Cross measure aims to slow runaway costs, improve quality of healthcare | www.boston.com
Author: GLG Expert Contributor
This plan would be worse than the capitated model because it would result in direct competition between the involved parties in a more complex network.  Primary care physicians may be incentived to limit referrals to specialists or to limit inpatient consultations.  Both primary care and specialists...
January 18, 2008
Quality or Profit ?
Analysis of: Insurers Stop Paying for Care Linked to Errors | online.wsj.com
Author: GLG Expert Contributor
Patient safety or corporate profits via any excuse for payment ?
January 16, 2008
Sanofi's Gardasil Should Be As Widely Accepted in Europe as in US
Analysis of: France Backs Sanofi's HPV Vaccine Gardasil Over Glaxo's | online.wsj.com
Author: GLG Expert Contributor
Sanofi's Gardisil, the first-to-market HPV vaccine for adolescent females, has been fairly widely accepted in the US, albeit with some concerns regarding adverse reactions and cost.  It is likely that EU sales will gradually increase as the vaccine is accepted in Europe as well.
December 19, 2007
Ustekinumab-new drug that gets to the core of psoriasis
Analysis of: Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis | www.jnj.com
Author: GLG Expert Contributor
This is exciting news in that P40 is a protein central to the pathogenesis of psoriasis and now utilizing this basic science knowledge long term remission of psoriasis, and inflammatory arthritis has occurred.  The good news is out. However, this is the first use of IL12/23 in human disease now...
December 19, 2007
Ustekinumab
Analysis of: Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis | www.jnj.com
Author: Jeffrey Weinberg, Director of Clinical Research - Dermatology, ST LUKE'S-ROOSEVELT HOSPITAL CENTER
This drug is four times yearly This will be attractive to MDs and patients It is highly efficaciuous
December 17, 2007
Reloxin Will Have a Huge Impact on Younger Women Entering Cosmetic Dermatology
Analysis of: Ipsen and Medicis announce submission of Reloxin(R) in aesthetics to the FDA | www.pipelinereview.com
Author: GLG Expert Contributor
Drysport has equivalent safety and efficacy data abroad to currently available Botox. A less expensive price point is anticipated.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next51 to 60 of 191

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617